|
Madrigal Pharmaceuticals, Inc. (MDGL) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Madrigal Pharmaceuticals, Inc. (MDGL) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem DCF -Taschenrechner von Madrigal Pharmaceuticals, Inc. (MDGL)! Erforschen Sie echte Finanzdaten, passen Sie Wachstumsprognosen und -kosten an und beobachten Sie sofort, wie diese Veränderungen den inneren Wert von Madrigal Pharmaceuticals (MDGL) beeinflussen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | 180.1 | 180.1 | 180.1 | 180.1 | 180.1 | 180.1 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -206.2 | -242.1 | -293.1 | -380.0 | -450.1 | 108.1 | 108.1 | 108.1 | 108.1 | 108.1 |
| EBITDA, % | 100 | 100 | 100 | 100 | -249.88 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .5 | .4 | .5 | .5 | 1.1 | 144.3 | 144.3 | 144.3 | 144.3 | 144.3 |
| Depreciation, % | 100 | 100 | 100 | 100 | 0.60844 | 80.12 | 80.12 | 80.12 | 80.12 | 80.12 |
| EBIT | -206.7 | -242.5 | -293.6 | -380.5 | -451.2 | 108.1 | 108.1 | 108.1 | 108.1 | 108.1 |
| EBIT, % | 100 | 100 | 100 | 100 | -250.49 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 284.1 | 270.3 | 358.8 | 634.1 | 926.3 | 180.1 | 180.1 | 180.1 | 180.1 | 180.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | 53.8 | 154.9 | 154.9 | 154.9 | 154.9 | 154.9 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 29.88 | 85.98 | 85.98 | 85.98 | 85.98 | 85.98 |
| Inventories | .0 | .0 | .0 | .0 | 34.1 | 150.9 | 150.9 | 150.9 | 150.9 | 150.9 |
| Inventories, % | 100 | 100 | 100 | 100 | 18.91 | 83.78 | 83.78 | 83.78 | 83.78 | 83.78 |
| Accounts Payable | 1.0 | 21.4 | 23.8 | 28.0 | 43.6 | 152.8 | 152.8 | 152.8 | 152.8 | 152.8 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 24.2 | 84.84 | 84.84 | 84.84 | 84.84 | 84.84 |
| Capital Expenditure | -.3 | -.2 | -.2 | -1.5 | -1.5 | -.3 | -.3 | -.3 | -.3 | -.3 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -0.81162 | -0.16232 | -0.16232 | -0.16232 | -0.16232 | -0.16232 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -201.8 | -241.7 | -297.5 | -380.5 | -451.2 | 107.5 | 107.5 | 107.5 | 107.5 | 107.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -200.6 | -221.2 | -294.8 | -377.2 | -523.9 | 142.9 | 251.5 | 251.5 | 251.5 | 251.5 |
| WACC, % | 5.17 | 5.17 | 5.18 | 5.18 | 5.18 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 980.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 257 | |||||||||
| Terminal Value | 8,082 | |||||||||
| Present Terminal Value | 6,281 | |||||||||
| Enterprise Value | 7,261 | |||||||||
| Net Debt | -99 | |||||||||
| Equity Value | 7,360 | |||||||||
| Diluted Shares Outstanding, MM | 21 | |||||||||
| Equity Value Per Share | 345.98 |
What You Will Get
- Real MDGL Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Madrigal Pharmaceuticals' future outlook.
- Clear and User-Friendly Design: Designed for professionals while remaining easy for newcomers.
Key Features
- 🔍 Real-Life MDGL Financials: Pre-filled historical and projected data for Madrigal Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Madrigal's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Madrigal’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Madrigal Pharmaceuticals, Inc. (MDGL).
- Step 2: Review Madrigal’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment decisions.
Why Choose This Calculator for Madrigal Pharmaceuticals, Inc. (MDGL)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for Madrigal Pharmaceuticals.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for MDGL.
- Detailed Insights: Automatically computes Madrigal’s intrinsic value and Net Present Value for informed decision-making.
- Preloaded Data: Access to historical and projected data ensures reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on MDGL.
Who Should Use This Product?
- Investors: Evaluate Madrigal Pharmaceuticals' valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation processes and assess financial forecasts.
- Startup Founders: Understand the valuation methods applied to biopharmaceutical companies like Madrigal.
- Consultants: Provide detailed valuation reports for clients in the healthcare sector.
- Students and Educators: Utilize real-world case studies to learn and teach valuation strategies.
What the Template Contains
- Historical Data: Includes Madrigal Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Madrigal Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Madrigal Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.